Clinical Study
Effects of Angiotensin Converting Enzyme Inhibitors on Liver Fibrosis in HIV and Hepatitis C Coinfection
Table 4
Number of subjects from each group with scores predictive of significant fibrosis at one year and three years (univariate analysis).
| Indices | Control group | ACE-I/ARB group | Odds ratio (95% confidence interval)* | P value |
| APRI score > 1.5 at one year (%) | 28 (23) | 10 (30) | 0.76 (0.41–1.40) | 0.39 | APRI score > 1.5 at three years (%) | 31 (24) | 7 (30) | 0.77 (0.39–1.54) | 0.48 | FIB4 score > 3.25 at one year (%) | 43 (35) | 16 (49) | 0.73 (0.48–1.11) | 0.17 | FIB4 score > 3.25 at three years (%) | 48 (36) | 11 (48) | 0.76 (0.47–1.23) | 0.30 | Forns score > 6.9 at one year (%) | 25 (50) | 14 (74) | 0.68 (0.46–1.00) | 0.08 | Forns score > 6.9 at three years (%) | 27 (47) | 12 (100) | 0.47 (0.36–0.62) | <0.001 |
|
|
*Odds ratio for an elevated score in the control group compared to the ACE-I/ARB group.
|